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Abstract
Neuropeptide Y (NPY) produced by arcuate nucleus (ARC) neurons has a strong orexigenic effect on target neurons.
Hypothalamic NPY levels undergo wide-ranging oscillations during the circadian cycle and in response to fasting and
peripheral hormones (from 0.25 to 10-fold change). The aim of the present study was to evaluate the impact of a moderate
long-term modulation of NPY within the ARC neurons on food consumption, body weight gain and hypothalamic
neuropeptides. We achieved a physiological overexpression (3.6-fold increase) and down-regulation (0.5-fold decrease) of
NPY in the rat ARC by injection of AAV vectors expressing NPY and synthetic microRNA that target the NPY, respectively.
Our work shows that a moderate overexpression of NPY was sufficient to induce diurnal over-feeding, sustained body
weight gain and severe obesity in adult rats. Additionally, the circulating levels of leptin were elevated but the
immunoreactivity (ir) of ARC neuropeptides was not in accordance (POMC-ir was unchanged and AGRP-ir increased),
suggesting a disruption in the ability of ARC neurons to response to peripheral metabolic alterations. Furthermore, a
dysfunction in adipocytes phenotype was observed in these obese rats. In addition, moderate down-regulation of NPY did
not affect basal feeding or normal body weight gain but the response to food deprivation was compromised since fasting-
induced hyperphagia was inhibited and fasting-induced decrease in locomotor activity was absent. These results highlight
the importance of the physiological ARC NPY levels oscillations on feeding regulation, fasting response and body weight
preservation, and are important for the design of therapeutic interventions for obesity that include the NPY.
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Introduction
Obesity and overweight are an increasing health problem
associated with the risk to develop life threatening conditions such
as diabetes, cardiovascular disease and cancer. The main cause of
obesity in the western society is the elevated consumption of high
caloric aliments and beverages, as well as decreased physical
activity.
Food intake and body weight gain are centrally regulated by the
hypothalamus, where arcuate nucleus (ARC) neurons have a key
role sensing and integrating peripheral signals of nutrition to
downstream circuits [1,2]. ARC neurons are divided into two
distinct populations acting together to regulate feeding behavior:
the orexigenic NPY/AGRP (Neuropeptide Y/Agouti-Related
Protein) neurons and the anorexigenic POMC/CART (Pro-
OpioMelanocortin/Cocaine-and-Amphetamine-Regulated-Tran-
script) neurons.
Most of the hypothalamic NPY-expressing neurons are located
in the ARC and project to different areas of the hypothalamus,
including the paraventricular nucleus (PVN), dorsomedial hypo-
thalamus (DMH), ventromedial hypothalamus (VMH) and lateral
hypothalamic area (LH) [3]. Other sources contribute to the
hypothalamic levels of NPY, such as a moderate number of NPY-
expressing neurons in the DMH [4,5]. NPY receptors are widely
distributed in hypothalamic nuclei and, in particular those
receiving NPY projections [6,7]. Within the hypothalamus, NPY
acts on down-stream target neurons, including neurons in the
PVN and LH, to produce feeding response [6,8,9].
In physiological conditions, NPY neurons located in the ARC
are controlled by multiple neural and peripheral signals. These
signals include the hormones leptin and insulin. Administration of
leptin or insulin suppresses the expression of NPY (about 0.5 to
1.5-fold decrease of ARC NPY levels) and reduces food intake in
lean rats [10,11,12,13] and in rodent models with elevated NPY
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[14,15,16,17]. In accordance, NPY neurons express the receptors
for these anorexigenic signals [18,19,20]. Another important
factor that influences NPY expression is fasting. NPY production is
stimulated by negative energy conditions, such that food depriva-
tion induces a potent up-regulation in the expression of NPY and
AGRP (5–10 fold increase as compared to basal) [21,22,23].
Furthermore, NPY levels return to initial values within 6 to
24 hours after re-feeding [21,24,25]. Additionally, the production
of NPY in ARC neurons is regulated by the circadian cycle. In
fact, ARC NPY concentrations oscillate during the light-dark cycle
[26], with a peak during the light-phase (1.25-fold increase in NPY
mRNA), that precedes the onset of nocturnal feeding and a
decrease to basal values during the dark-phase. Moreover, the
resultant release of NPY in the PVN is higher during the same
period [24,27].
Alterations in the hypothalamic NPY levels are also associated
to obesity. In average, a 3-fold increase in NPY expression in the
ARC and release in the PVN is observed in rodent models of
obesity, including Zucker rats [28,29,30] and the db/db and ob/
ob mice [14,30,31,32]. Interestingly, the obese Zucker rats do not
show the typical peak of NPY release at the light-dark transition,
neither the circadian rhythm of feeding observed in lean rats [33].
In addition, some studies also report elevated levels of hypotha-
lamic NPY (30%, in average) in diet-induced obese mice (DIO)
[34,35]. However, other studies show a compensatory down-
regulation of NPY expression in the ARC and immunoreactivity
in the PVN in rats fed with high-fat diet for variable periods of
time [36,37,38], which was related to the inhibitor effect of
elevated leptin concentrations.
So far, several pharmacological and genetic studies were
performed in order to better understand the role of NPY on
feeding behavior and obesity. For example, central administration
of NPY by i.c.v. injection or directly into the PVN induces a robust
feeding response [39,40,41] and chronic administration of NPY
produces continuous hyperphagia, leading to obesity [42,43].
Moreover, sustained viral overexpression of NPY on hypothalamic
nuclei such as the PVN, LH and DMH, results in increased food
intake and body weight gain compared to controls, with rats
developing obesity [44,45,46]. However, the extent to which these
modifications are observed is different, underlying the divergent
contributions of hypothalamic nuclei to energy balance regulation.
In opposition, NPY deletion on knock-out mice [47] or ablation of
NPY neurons in neonatal mice [48] does not significantly affect
feeding or body weight. However, ablation of NPY neurons in the
ARC of adult mice leads to starvation [48,49]. Furthermore,
sustained down-regulation of ARC NPY by RNA-interference
inhibits re-feeding response after fasting in adult rats, but its effects
on basal food consumption or body weight were not reported [46].
In conclusion, some of these studies evoke a severe activation or
total ablation of the hypothalamic NPYergic system, which may
not reflect the physiological oscillations of NPY owning to the
nutritional condition.
In the present study, we investigated the impact of a modest but
sustained modulation of NPY within the ARC neurons on food
consumption and body weight gain. The ARC is a hypothalamic
nucleus of particular interest, not only because it is the primary
source of hypothalamic NPY, but also because ARC neurons are
highly regulated by compensatory mechanism and, so far, it is not
known whether viral NPY modulation in the ARC would result or
not in energy balance alterations. To achieve our aim, we
overexpressed and down-regulated NPY expression in the adult
rat ARC, by injection of AAV vectors expressing NPY and
synthetic microRNA that target NPY, respectively. Our work
shows that a moderate overexpression of NPY was sufficient to
induce over-feeding, sustained body weight gain and severe obesity
in adult rats. While the moderate down-regulation of NPY did not
affect basal feeding or normal body weight gain but impaired the
response to fasting.
Results
In vitro validation of AAV vectors for overexpression and
down-regulation of NPY
To over-express NPY in the ARC neurons we cloned the Npy
cDNA into the AAV back-bone (Fig. 1A). To down-regulate the
NPY expression we cloned three synthetic microRNAs (miR)
targeting different sites of the NPY mRNA (Fig. 1B) into the AAV
backbone (Fig. 1A). Additionally, we cloned one microRNA with a
random sequence into the AAV backbone to be used as control
(miR-ctr).
We screened the microRNAs for their efficacy to down-regulate
the NPY expression by co-transfecting HEK293 cells with the
pAAV-hSyn-NPY plasmid and each one of the different pAAV-
hSyn-miR-NPY plasmids. NPY peptide levels were quantified by
immunoblotting and densitometry band evaluation (Fig. 1C), using
miR-ctr as control. The miR-NPY3 achieved the strongest NPY
down-regulation (53.4614.5% compared to miR-ctr control) and
was chosen for further in vivo studies.
Furthermore, to validate the ability of AAV vectors to transduce
and express the transgene in NPY positive neurons, we infect a rat
neuronal culture with AAV vectors expressing EGFP. As seen by
the co-localization of EGFP and NPY immunoreactivity (NPY-ir)
in (Fig. 1D), these viral vectors can transduce the target cells (NPY-
expressing neurons) and efficiently express the transgene.
AAV-mediated moderate overexpression and down-
regulation of NPY in ARC neurons of adult rats
Modulation of ARC NPY expression was achieved as shown in
the representative images of NPY immunoreactivity (Fig. 2A and
Fig. 2B). The levels of NPY-ir were quantified bilaterally through
the rostro-caudal length of the ARC (Fig. 2C), eight weeks after
AAV injection, in the following three groups: A) Control group
(ARC-miR-ctr), B) ARC NPY down-regulation group (ARC-miR-
NPY), and C) ARC NPY overexpression group (ARC-NPY). The
NPY-ir levels were 50% lower in the ARC-miR-NPY group and
3.6-fold higher in the ARC-NPY group compared to ARC-miR-
ctr group (49.0615.7 a.u., 359.1632.1 a.u. and 97.2619.4 a.u.,
respectively). This moderate modulation of ARC NPY levels
allows the development of a physiologically relevant study.
Additionally, the levels of NPY-ir were evaluated in the area
surrounding the ARC to confirm that the NPY modulation was
mainly restricted to the ARC. NPY-ir in the medial hypothalamic
nuclei VMH/DMH were not statistically different between the
three groups (p.0.05; n=6; One-Way ANOVA). The values
obtained were: ARC-miR-ctr, 124.364.8 a.u.; ARC-miR-NPY,
99.4610.0 a.u.; and, ARC-NPY, 181.9623.8 a.u.
ARC NPY overexpression induces sustained body weight
gain and severe body fat accumulation
We evaluated the impact of ARC NPY modulation on body
weight gain (Fig. 3A). The ARC-NPY rats showed a fast and
sustained increase on body weight gain, weighting 220 g more
than the ARC-miR-ctr rats (351.4643.3 g and 129.9620.3 g of
cumulative weight gain, respectively), six weeks after AAV
injection; and having 88% higher body weight gain than ARC-
miR-ctr group at the end of the study. In contrast, ARC-miR-NPY
NPY in ARC and Energy Balance Alterations
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representation of the AAV vectors. The NPY expression vector contains one cassette to express NPY under a neuronal specific promoter. The
microRNA expression vector contains one cassette with co-cistronic expression of EGFP and miR under the neuronal specific promoter. ITR, inverted
terminal repeats; hSyn, human Synapsin promoter; WPRE, woodchuck hepatitis virus posttranslational control element; PolyA, polyadenosine
sequence. Small human synapsin 1 gene promoter has shown to drive long-term neuron specific transgene expression from AAV-2 vectors [88]. (B)
Three synthetic microRNA directed to different regions of NPY mRNA and one control microRNA (random sequence) were cloned. (C) Screen of
microRNA targeting NPY. Representative image of NPY expression and densitometry band evaluation normalized to a-tubulin and shown as
percentage of miR-ctr. Cells co-transfected with the NPY vector and one of the miR-NPY vectors, in a 1:1 ratio. NPY expression is significantly reduced
with the miR-NPY-3 vector. n=3 independent cell transfection; * p,0.05 compared to miR-ctr control. (D) Transduction of NPY positive neurons (red)
by AAV-hSyn-miR cassette (EGFP-green) in primary neuronal culture. Scale bar, 20 mm.
doi:10.1371/journal.pone.0022333.g001
Figure 2. Modulation of NPY expression in the rat ARC via bilateral injection of AAV. (A) Representative images of NPY immunoreactivity
(white) in the rat ARC modulated by AAV injection. Scale bar, 100 mm. (B) High magnification of representative images of ARC NPY immunoreactivity
modulated by AAV injection. Scale bar, 100 mm. (C) Bilateral quantification of NPY immunoreactivity quantified through the rostro-caudal length of
the rat ARC, eight weeks after AAV injection. ARC NPY immunoreactivity is 50% lower on the ARC-miR-NPY group and 3.6-fold higher on the ARC-NPY
group, compared to ARC-miR-ctr group. n=6 rats per group; ** p,0.01; *** p,0.001 compared to ARC-miR-ctr. ir, immunoreactivity.
doi:10.1371/journal.pone.0022333.g002
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compared to control group (Fig. 3A).
Eight weeks after AAV injection, ARC-NPY rats exhibited an
obese phenotype and staring coat (Fig. 3B). These rats had
enlarged pale liver and excessive visceral adipose tissue deposit.
Severe body fat accumulation on ARC-NPY rats was confirmed
by the 266% higher epididymal fat pad weight compared to ARC-
miR-ctr and ARC-miR-NPY group (32.366.0 g, 8.862.6 g and
9.163.3 g, respectively) (Fig. 3C).
ARC NPY overexpression causes serum alterations
consistent with obesity and elevated serum NPY
Serum analyzes were performed to evaluate possible alterations
consistent with the observed obese phenotype in ARC-NPY rats.
Results are summarized on Table 1. The levels of glucose,
cholesterol, aspartate-amino-transferase, alanine-amino-transfer-
ase and C-reactive-protein were robustly increased in the ARC-
NPY group but the triglycerides (TG) levels were not statistically
different from the control group. Furthermore, the ARC-NPY
Figure 3. Overexpression of NPY in the ARC induces sustained body weight gain and severe fat accumulation while down-
regulation of ARC NPY does not affect the body weight gain. (A) Cumulative body weight gains presented as percentage of initial weight in
the control, ARC-miR-NPY and ARC-NPY groups. Boxes indicates food deprivation period (FD). n=6 rats per group; * p,0.05; *** p,0.001, compared
to ARC-miR-ctr group. (B) Representative images of rats and (C) epididymal fat pad weight, eight weeks after AAV injection, showing the obese
phenotype and severe body fat accumulation in rats with ARC-NPY overexpression. n=6 rats per group; ns p.0.05; *** p,0.001, compared to ARC-
miR-ctr group.
doi:10.1371/journal.pone.0022333.g003
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ARC-miR-ctr group. Interestingly, higher values of serum NPY
were observed on the obese ARC-NPY group compared to the
lean ARC-miR-ctr group. No significant differences were observed
on serological parameters between the ARC-miR-NPY and ARC-
mir-ctr groups.
ARC NPY overexpression increases adipocytes size and
decreases PPAR-gamma-2 adipogenic marker in white
adipose tissue
We assessed possible phenotype alterations on the white adipose
tissue (WAT) upon modulation of ARC NPY by evaluation of
adipocytes size and differentiation marker Peroxisome Proliferator
Activated Receptor type 2 (PPAR-gamma-2), eight weeks after
AAV injection. Sections from epididymal fat pad were analyzed
by fluorescence microscopy (Fig. 4A) and adipocytes average
diameter was measured and grouped by size range (Fig. 4B). The
distribution of adipocytes size was not different between the ARC-
miR-ctr and ARC-miR-NPY group. However, the obese ARC-
NPY group showed a higher percentage of large adipocytes and a
reduced percentage of small adipocytes, compared to lean ARC-
miR-ctr group (large adipocytes: range of 140–180 mm 34.66
6.3% and 0.860.6%, respectively and range of 180–220 mm
19.767.5% and 0.0%, respectively; small adipocytes: range of 60–
100 mm 11.963.8% and 57.2614.6%, respectively).
Furthermore, we measured PPAR-gamma protein levels in
WAT extracts by immunoblotting (Fig. 4C and 4D). Unexpect-
edly, we observed 41% lower levels of adipogenic marker PPAR-
gamma-2 on WAT from obese ARC-NPY rats compared to lean
ARC-miR-ctr rats (0.1260.01 a.u. and 0.2160.03 a.u., respec-
tively). No differences were observed on the PPAR-gamma-2
expression in ARC-miR-NPY group compared to control. The
specificity of alteration on adipogenic PPAR-gamma-2 was con-
firmed by evaluation of ubiquitous PPAR-gamma-1. As expected,
the levels of PPAR-gamma-1 protein were similar in the WAT
samples from the three groups. These results suggest that in this
obesity model there is a dysfunction in adipocytes phenotype,
characterized by adipocytes with higher diameter but decreased
PPAR-gamma-2 expression.
Obesity induced by ARC NPY overexpression results from
increased diurnal food intake
To test if viral modulation of NPY in the ARC would influence
the normal food intake during the circadian cycle, we monitored
the feeding patterns of rats during the 8 weeks following AAV
injection. Six weeks after AAV injection, the ARC-miR-ctr and
the ARC-miR-NPY group presented a similar food intake while
the ARC-NPY group consumed 1.7-times more food a day than
the control group (Fig. 5A). The overfeeding pattern presented by
the ARC-NPY group was predominantly due to a 2.8-fold increase
on food intake during the light period compared to ARC-miR-ctr
group (17.462.5 g/12 hours and 6.261.5 g/12 hours, respective-
ly); while the food intake observed on the dark period was not
significantly different from the ARC-miR-ctr control. Therefore,
modest sustained overexpression of NPY in the ARC is sufficient
to induce over-feeding and abolish the normal daily feeding
pattern.
AAV-mediated modulation of ARC NPY disrupts fasting-
induced responses
To further investigate the regulation of feeding upon viral ARC
NPY modulation, we tested the fasting-induced hyperphagia with
re-feeding in the beginning of the nocturnal and diurnal periods
(Fig. 5B). The control ARC-miR-ctr group presented the typical
fasting induced hyperphagia with 200% increase on food intake
upon re-feeding on the light period, compared to basal (16.26
0.6 g/12 hours and 5.660.5 g/12 hours, respectively) and 25.0%
increase on food intake upon re-feeding on the dark period,
compared to basal (26.162.0 g/12 hours and 20.961.9 g/
12 hours, respectively). Conversely, ARC-NPY group did not
had a significant increase on food intake upon re-feeding on the
light period compared to control group (15621.3% of basal and
192635.3% of basal, respectively) (Fig. 5B-i); however these rats
already had elevated food consumption on the diurnal period
(Fig. 5A). Moreover, the fasting-induced hyperphagia showed
by ARC-NPY rats upon re-feeding on the dark period was
significantly lower when compared to control group hyperphagia
(7.164.2% of basal and 25.061.8% of basal, respectively) (Fig. 5B-
ii), despite the normal basal food consumption on the dark period
(Fig. 5A). These evidences suggest that sustained overexpression of
NPY in ARC neurons interrupts the feeding sensing mechanism.
Fasting-induced hyperphagia was inhibited by the down-
regulation of ARC NPY in the ARC-miR-NPY rats. In fact,
these animals exhibited only 56% of the increase on food intake
observed in control animals upon re-feeding the light period
(9.560.6 g/12 hours after FD and 16.260.6 g/12 hours after
FD, respectively) (Fig. 5B-iii). And 30% of the response observed in
the control group upon re-feeding on the dark period (7.665.5%
of basal and 25.061.8% of basal, respectively) (Fig. 5B-iv),
indicating that fasting-induced hyperphagia is mediated by the
increase in NPY levels at the ARC. The observed effects of ARC
NPY modulation on fasting-induced feeding are summarized in
Figure 5C.
Additionally, we evaluated the locomotor activity on satiated
and food-deprived rats (Fig. 5D), on the fifth week after AAV
injection. The control ARC-miR-ctr group exhibited a 40%
decrease on its locomotor activity after 24 hours of FD, compared
to basal (94.069.3 crossings/10 minutes and 157.0618.7 cross-
ings/10 minutes, respectively). Interestingly, on the ARC-miR-
NPY group the locomotor activity level was not decreased under
FD condition, compared to basal (140.3629.1 crossings/10 min-
utes and 147.3629.1 crossings/10 minutes, respectively). In
contrast, the ARC-NPY group showed low locomotor activity
Table 1. ARC NPY overexpression causes serum alterations
consistent with obesity and elevated serum NPY.
ARC-miR-ctr ARC-miR-NPY ARC-NPY
Glucose (mg/dl) 95.0610.7 92.766.7
a 397.56118.5
c
Cholesterol (mg/dl) 37.362.3 45.867.6
a 233.0616.0
c
Triglycerides (mg/dl) 98.5615.5 82.867.3
a 121.5621.5
a
Aspartate-amino-transferase (IU/L) 55.067.0 58.865.3
a 221.5649.5
c
Alanine-amino-transferase (IU/L) 30.565.5 34.565.5
a 187.0637.5
c
C-reactive-protein (mg/dl) 7.760.2 7.160.4
a 10.760.8
c
Insulin (ng/mL) 5.561.9 8.166.6
a 164.9650.9
c
Leptin (ng/mL) 9.963.3 11.667.7
a 266.2653.9
c
NPY (ng/mL) 1.660.3 0.960.3
a 3.660.6
b
Serum analysis of control, ARC-miR-NPY and ARC-NPY rats, eight weeks after
AAV injection. Biochemical analysis of serum from rats fed on standard chow
diet. n=5/6 rats per group for glucose, leptin and insulin and n=4 rats per
group for the other parameters.
a,p .0.5;
b,p ,0.01;
c,p ,0.001, compared to ARC-miR-ctr control.
doi:10.1371/journal.pone.0022333.t001
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and 55.0614.7 crossings/10 minutes, respectively). These results
suggest that ARC NPY is necessary to the fasting-induced
reduction of activity.
Overexpression of ARC NPY deregulates feed-back
mechanisms in the ARC
To evaluate the existence of possible compensatory mechanism
caused by ARC NPY overexpression or down-regulation, we
evaluated the levels of appetite-related neuropeptides in the ARC.
For this purpose we quantified the immunoreactivity (ir) of AGRP,
POMC and CART bilaterally in the ARC, eight weeks after AAV
injection. Unexpectedly, immunohistochemical analyses for orexi-
genic AGRP (Fig. 6A and 6D), revealed significantly higher
AGRP-ir on the ARC-NPY group, compared to ARC-miR-ctr
group (166.2635.9 a.u. and 96.666.9 a.u., respectively) while no
differences were observed concerning AGRP-ir on the ARC-miR-
NPY group (90.0615.1 a.u.). Additionally, immunohistochemical
evaluation of anorexigenic POMC (Fig. 6B and 6E), showed no
differences on POMC-ir on the ARC-miR-NPY and ARC-NPY
groups, compared to ARC-miR-ctr group (163.865.0 a.u., 170.7
616.0 a.u. and 168.2640.9 a.u., respectively). Finally, immuno-
histochemical analyses for anorexigenic CART (Fig. 6C and 6D),
revealed higher CART-ir on the ARC-NPY group, compared to
ARC-miR-ctr control group (155.1620.1 a.u. and 98.363.2 a.u.,
respectively) and no difference concerning CART-ir on the ARC-
miR-NPY group (109.068.2 a.u.), compared to control. These
results show that the moderate down-regulation of ARC NPY
does not produce compensatory changes on ARC neuropeptides
expression. Moreover, the AGRP up-regulation and absence of
POMC increase are not in accordance with the elevated levels of
circulating leptin suggesting a deregulation of the appetite related
feed-back mechanisms in rats with ARC NPY overexpression.
Discussion
In the present study we demonstrated that moderate long-term
modulation of NPY levels in the ARC of adult rats is sufficient to
affect feeding behavior and body weight gain. We showed that up-
regulation of ARC NPY results in diurnal overfeeding, with
disruption of feeding patterns and inhibition of fasting-induced
hyperphagia. Moreover, it results in a severe obese phenotype that
is not prevented by the elevated levels of circulating leptin.
Additionally, we reported that modest sustained down-regulation
of ARC NPY does not alter food intake on basal conditions, but
inhibits fasting-induced hyperphagia. These results highlight the
importance of the physiological ARC NPY levels oscillations,
occurring during the circadian cycle and in response to energetic
alterations, on feeding regulation and fasting-induced response, as
well as in body weight preservation and, possibly, in the prevention
of obesity. Overall, these findings may be important for the design
of therapeutic interventions for obesity that include the NPY.
Moderate overexpression of ARC NPY
The expression of feeding-related neuropeptides in ARC
neurons is regulated by the energetic condition of the organism.
In particular, the expression of orexigenic peptides NPY and
AGRP is potently up-regulated by fasting (5–10 fold increase
as compared to basal) [21,22,23]. In opposition, the levels of
anorexigenic POMC are only modestly decreased with fasting
(20–50% decrease as compared to basal) [50,51]. In our study, the
moderately increase on NPY levels in the ARC (3.6-fold as
compared to controls) was sufficient to induce obesity, suggesting
Figure 4. ARC NPY overexpression increases adipocytes size and decreases PPAR-gamma-2 adipogenic marker in white adipose
tissue. Evaluation of adipocytes size and differentiation markers (Peroxisome Proliferator Activated Receptor type 2, PPAR-gamma-2), eight weeks
after AAV injection. (A) Representative images of adipocytes auto-fluorescence from ARC-miR-ctr, ARC-miR-NPY and ARC-NPY groups. Scale bar,
100 mm. (B) Adipocytes size distribution represented as percentage of total number of adipocytes. n=6 rats per group; ns, non-significant, ** p,0.01;
*** p,0.001 compared to ARC-miR-ctr group size range. (C) Evaluation of PPAR-gamma isoforms in epididymal adipose tissue extracts by
immunobloting. Representative images of protein level. The expression of PPAR-gamma-2 isoform is lower on ARC-NPY obese rats, compared to ARC-
miR-ctr rats. (D) Densitometry band evaluation normalized to b-actin and shown as percentage of ARC-miR-ctr. n=3/4 rats per group; ns p.0.5;
*p ,0.5, compared to ARC-miR-ctr group. ir, immunoreactivity.
doi:10.1371/journal.pone.0022333.g004
NPY in ARC and Energy Balance Alterations
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ARC is sufficient to severely alter the energy balance. Interest-
ingly, the increase of ARC NPY levels in our model is in ac-
cordance to the up-regulation observed in genetic obesity models,
such as the Zucker rats (3-fold increase in hypothalamic NPY
content) [28,29,30]. However, it is not possible to compare it with
the studies showing viral overexpression of NPY in the PVN and
LH since the authors did not provide a quantification for the NPY
overexpression levels [44,52].
Nevertheless, our study shows that overexpression of NPY in
ARC neurons resulted in a more severe obese phenotype than the
overexpression on target neurons observed by others [44,52]. For
example, ARC-NPY rats weighted 200 g more than controls,
while PVN-NPY rats weighted approximately 75 g more and LH-
NPY rats weighted approximately 100 g more than controls, 50 to
60 days after the AAV injection [44,52]. Obesity induced by NPY
overexpression resulted from diurnal hyperphagia in the three
models. In fact, normal rats eat approx. 6 g of food in the diurnal
period but rats with ARC-NPY overexpression eat approx. 17 g of
food, while rats with PVN-NPY overexpression and LH-NPY
overexpression eat approx. 9 and 12.5 g of food in the same
period, 40 to 50 days after the AAV injection [44,52]. Thus, our
study demonstrates that overexpression of NPY in the ARC results
in a stronger hyperphagic phenotype when compared to over-
expression of NPY on target neurons. Despite the fact that these
divergences may be owing to technical differences including the
viral titer injected and the promoter used, the severe obese pheno-
type observed upon ARC NPY overexpression emphasizes the
importance of the ARC NPY to the control of feeding.
Sustained up-regulation of hypothalamic NPY is associated to a
disruption of feeding patterns in rodent models of obesity such as
Zucker rats [33], rats overexpressing NPY in the LH [44] and, as
reported in this study, rats overexpressing NPY in the ARC. These
observations highlight the crucial role of hypothalamic NPY
oscillations during the circadian cycle to keep feeding patterns,
preserve body weight and, possibly, prevent obesity in rodents.
Moreover, these findings are important because deregulation of
the circadian cycle in humans, as for example in nocturnal feeding,
sleep loss and shift work, results in significant changes on feeding
behavior and has been described as a risk factor for obesity
[53,54,55].
In physiological conditions, the expression of ARC neuropep-
tides is regulated by compensatory peripheral mechanisms,
including the hormone leptin, produced by adipocytes in propor-
tional quantities to body fat storages [56,57]. Leptin inhibits the
Figure 5. Viral modulation of ARC NPY alters feeding behavior
and disrupts fasting-induced responses. (A) ARC NPY overexpres-
sion increases diurnal but not nocturnal food intake compared to
control; whereas ARC NPY down-regulation does not change food
intake compared to control. Food intake was measured on 12-hours-
dark, 12-hours-light and 24-hours, six weeks after AAV injection. n=6
rats per group. ns p.0.5; *** p,0.01 compared to ARC-miR-ctr group.
(B) Fasting induced hyperphagia is disrupted by viral ARC NPY
overexpression (i and ii) and viral ARC NPY down-regulation (iii and
iv). Food intake was evaluated after 36-hours of food deprivation (FD)
with re-feeding on the light (i and iii), and on the dark period (ii and
iv). Data is presented as percentage of food intake increase induced by
fasting, on a 12-hour period. n=3 rats per group. * p,0.5; ** p,0.01
compared to ARC-mir-ctr group. (C) Table showing the effect of ARC
NPY levels on basal food intake and on the increase of food intake after
FD. (D) ARC NPY modulation impairs the locomotor activity on FD
condition, five weeks after AAV injection. Data is presented as total
number of crossings per 10 minutes. n=3 rats per group. ns p.0.5;
*p ,0.5 compared to basal.
doi:10.1371/journal.pone.0022333.g005
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15,23] and increases the expression of POMC and CART
[51,58,59]. Moreover, ARC NPY expression is regulated in an
autocrine manner via presynaptic NPY Y2 receptors, present in
NPY neurons and acting to decrease NPY expression [60,61,62].
The present study shows that a modest overexpression of NPY
in the rat ARC neurons results in excessive body weight gain and
fat accumulation and hyperleptinemia, demonstrating that the
compensatory mechanisms regulating NPY expression are not
ineffective in this condition. Moreover, several evidences in our
work point to a disruption in the ability of ARC neurons to
response to metabolic alterations. For example, the inhibitory
effect of elevated concentrations of leptin and auto-inhibitory
effect of NPY were not sufficient to restore the NPY levels. In
addition, rats over-expressing NPY in the ARC did not response to
fasting on the dark period, when their basal food intake was
normal. And finally, the levels of ARC neuropeptides were not in
accordance with the elevated levels of leptin (POMC immunore-
activity was unchanged and AGRP immunoreactivity was
increased).
The fact that rats overexpressing NPY have alterations in the
neuropeptides levels which are not consistent with hyperleptine-
mia can result from the paracrine effect of NPY on ARC neurons.
Leptin acts to increase the expression of POMC [51] but, in this
Figure 6. Overexpression of ARC NPY deregulates feedback mechanism in the ARC. Representative immunostaining images of ARC
peptides immunoreactivity: (A) AGRP, (B) POMC and (C) CART. Bilateral quantification of ARC peptides immunoreactivity evaluated through the
rostro-caudal length of the rat ARC, eight weeks after AAV injection: (D) AGRP, (E) POMC and (F) CART. Scale bar, 100 mm. n=3/4 rats per group. ns
p.0.5; * p,0.5; *** p,0.01 compared to ARC-miR-ctr. ir, immunoreactivity.
doi:10.1371/journal.pone.0022333.g006
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neurons may be counteracting this effect. In fact, NPY and
POMC neurons establish a functional network, formed mainly by
dense NPY/AGRP fibers projecting to POMC cell bodies [63].
The release of NPY inhibits POMC neurons through activation
of NPY Y1 and Y2 receptors expressed by POMC neurons
[60,61,63,64]. Moreover, NPY i.c.v. infusion decreases the
expression of POMC in rats and mice [65,66]. Additionally,
elevated NPY concentrations may also oppose the inhibitory effect
of leptin in AGRP levels since NPY can up-regulate AGRP
immunoreactivity, as shown in hypothalamic explants [67]. It
should also be considered that viral expression of NPY is occurring
in ARC neurons with distinct phenotypes, which could be further
contributing to the deregulation of feeding circuits and ineffec-
tiveness of peripheral compensatory mechanisms. For example,
the expression of NPY in anorexigenic ARC neurons, such as
POMC or neurotensin neurons, which are activated by circulating
leptin [63,68], may be inducing a further increase in NPY
expression in these neurons.
Another factor contributing to the inconsistent levels of ARC
neuropeptides observed in hyperleptinemic ARC-NPY rats may
be the development of leptin resistance by hypothalamic neurons.
In fact, the number of leptin-activated neurons in the ARC is
significantly reduced in DIO mice, positioning the ARC as a
major site of leptin resistance [69,70]. Moreover, leptin respon-
siveness by NPY/AGRP and POMC neurons is drastically
decreased in DIO mice [71] and after chronic leptin treatment
[13,72].
Interestingly, in these obese rats, the levels of CART were
moderately increased compared to controls, suggesting that
CART expression is responding to the high levels of leptin.
On the peripheral level, obese ARC-NPY rats revealed an
increase in the number of large adipocytes along with a decrease in
mature adipocytes marker PPAR-gamma-2 levels in white adipose
tissue (WAT), suggesting a dysfunction in the adipocytes of severe
obese rats. This dysfunction may be related to hypoxia that occurs
in the adipose tissue of obese mice proportionally to body fat
gain [73,74]. Hypoxia promotes a decrease in PPAR-gamma-2
expression in adipocytes [75,76], and can explain the down-
regulation of this protein in our model. Moreover, obese ARC-
NPY rats presented high NPY serum levels as compared to
controls underlie the contribution of sympathetic NPY to the
development of obesity [77,78,79].
Moderate down-regulation of ARC NPY
The silencing strategy applied in this work, AAV vectors
delivering synthetic microRNA that target NPY, could only
achieve a 50% down-regulation in the ARC NPY immunoreac-
tivity. These subtle silencing levels may be owing to a non total
transduction of the NPY expressing cells by the AAV vectors,
despite the fact that EGFP expressing cells were found throughout
the length of the ARC (data not shown). Moreover, the non-
transduced NPY neurons may be overriding to compensate for
those transduced with the miR-NPY, thus decreasing the silencing
levels. Nevertheless, the 50% down-regulation of ARC NPY
expression meets our aim of obtaining a modest modulation of
NPY. In fact, leptin and insulin can have an equivalent or stronger
inhibitory effect in the ARC NPY expression, achieving about 0.5
to 1.5-fold decrease of ARC NPY levels in normal, fasted or
diabetic rats [11,15,16].
In the present study, sustained inhibition of NPY expression in
the ARC of adult rats was not sufficient to cause alterations on
food intake and body weight gain in basal conditions. These results
may seem surprisingly weak when compared to the severe
phenotype observed upon ARC NPY overexpression, but ARC
NPY down-regulation does not necessarily represents the opposite
of NPY overexpression. In fact, overexpression of an anorexigenic
neuropeptide, as for example POMC or its cleavage product of a-
melanocyte stimulating hormone (a-MSH), would correspond to
the opposite experiment of NPY overexpression. As reported by
others, AAV-mediated overexpression of POMC in the ARC
results in decreased food intake, body weight and adiposity in age-
related obese rats and Zucker obese rats, with an improvement of
the metabolic parameters [80,81].
Deletion of NPY in embryos or neonatal mice [47,48],
progressive loss of hypothalamic NPY neurons [82] and, as shown
in this study, moderate down-regulation of NPY expression in the
ARC of adult rats does not induce alterations on basal feeding
behavior. However, our work demonstrate that the response to
challenging situations, like food deprivation, is impaired such that
fasting-induced hyperphagia or fasting-induced decrease on loco-
motor activity are absent in rats with down-regulation of ARC
NPY levels. Our findings obtained from specific down-regulation
of NPY in ARC neurons confirms that fasting-induced responses
are mediated by the increase of NPY expression in the ARC
neurons [4,21].
Nevertheless, our results are not in accordance with previous
studies reporting reduced food intake and cumulative weight gain
after down-regulation of ARC NPY by anti-sense oligonucleotides
(AS-NPY) [83]. Despite the fact that both studies use the same
vector (AAV), other technical aspects may explain the divergent
observation. First, the silencing strategies used in the studies are
different. In fact, Gardiner et al. [83] delivered anti-sense oligo-
nucleotides under the control of an ubiquitous CMV promoter.
Anti-sense oligonucleotides inhibit the transcription of mRNA to
protein by physically blocking the access of ribosome to mRNA
and/or activation of RNase H, which will cleave the DNA-RNA
heteroduplex [84]. In opposition, we delivered artificial micro-
RNAs under the control of a neuron-specific polymerase II pro-
moter. The artificial microRNAs take part of the RNA-induced
silencing complex (RISC) and bind to the target mRNA in a
sequence-specific manner, promoting gene silencing. This novel
RNA interference mechanism has proven to mitigate RNAi-
mediated toxicity in the brain [85]. Therefore, the more specific
(expression of microRNA exclusive in neurons) strategy employed
in the present work may account for some of the reported
differences. Finally, we evaluated the ARC NPY down-regulation
by quantification of NPY immunoreactivity in brain sections while
Gardiner et al. [83] measured the levels of NPY released from
hypothalamic explants. Since the techniques used to assess the
NPY down-regulation are different, we cannot compare accurately
the silencing levels achieved with the two strategies.
Down-regulation of ARC NPY was not compensated with
alterations on other ARC neuropeptides (immunoreactivity for
AGRP, POMC and CART was unchanged compared to controls)
which can be explained by two reasons: 1) compensatory changes
that may occur to keep food intake quantities are not mediated by
alterations in the expression of these neuropeptides, or 2) sustained
50% decrease of NPY levels is not sufficient to produce com-
pensatory alterations on these neuropeptides.
Conclusions
All together, our data shows that sustained moderate up-
regulation of orexigenic NPY in the ARC results in diurnal over-
feeding and disruption of the compensatory feeding responses. In
addition, specific down-regulation of this orexigenic signal inhibits
the fasting induced responses. These results highlight the impor-
tance of the physiological ARC NPY levels oscillations on feeding
NPY in ARC and Energy Balance Alterations
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preservation and, possibly, in the prevention of obesity. The
findings here reported are important for the design of therapeutic
interventions for obesity that include the NPY.
Methods
Animals
Male Wistar rats were purchased from Charles River Labora-
tories. Rats were individually housed under a 12 h light/dark cycle
in a temperature/humidity controlled room with ad libitum access
to water and a standard chow diet. All experimental procedures
were performed in accordance with the European Union Directive
86/609/EEC for the care and use of laboratory animals. More-
over, all the people working with animals have received appro-
priate education (FELASA course) as required by the Portuguese
authorities. In addition, animals are housed in our licensed animal
facility (international Animal Welfare Assurance number
520.000.000.2006). The present study is included in a project
approved and financed by the Portuguese science foundation that
approved the animal experimentation described. CNC animal
experimentation board approved the utilization of animals for this
project (reference PTDC/SAU-FCF/099082/2008).
Construction of NPY and microRNA expression vectors
Rat NPY cDNA from p46F06444D-NPY (RZPD) was cloned
into AAV back-bone. Three microRNA (miR) expression vectors
were constructed using the BLOCK-iT Pol II miR RNAi Ex-
pression Vector Kit (Invitrogen). Oligonucleotides targeting the rat
NPY mRNA were designed and cloned into the pcDNA6.2GW/
EmGFP-miR vector. The miR control plasmids pcDNA6.2GW/
EmGFP-miR-control (random sequence) was provided with the
BLOCK-iT Pol II miR validated miRNA Control Vectors kit
(Invitrogen). The sense sequences of the cloned microRNAs was:
miR-1, 59TGCTGCAAACACACGAGCAGGGATAGGTTTT-
GGCCACTGACTGACCTATCCCTTCGTGTGTTTG39;miR-
2, 59TGCTGAGAATGCCCAAACACACGAGCGTTTTGGC-
CACTGACTGACGCTCGTGTTTGGGCATTCT39; miR-3,
59TGCTGTGAGATTGATGTAGTGTCGCAGTTTTGGCC-
ACTGACTGACTGCGACACCATCAATCTCA39; and miR-
ctr, 59TGCTGAAATGTACTGCGCGTGGAGACGTTTTGG-
CCACTGACTGACGTCTCCACGCAGTACATTT39. The EGFP
and miR sequences were cloned into the AAV back-bone by
performing a BP/LR recombination.
In vitro screen of microRNAs
For the validation of NPY vector and synthetic microRNA,
HEK 293 cells (American Type Culture Collection, ATCC CRL-
11268, Manassas, USA, ATTC) were co-transfected with pAAV-
hSyn-NPY and one of the pAAV-hSyn-miR plasmids, in a 1:1
ratio, using standard calcium phosphate method. Forty-eight
hours after transfection, cell lysates were obtained and thirty
micrograms of protein were used for 16% polyacrylamide gel
Tricine-SDS electrophoresis. Protein samples were transferred to a
0.22 mm nitrocellulose membrane (Applichem). The membrane
was incubated with anti-NPY antibody (1:3000, Sigma) overnight
at 4uC followed by incubation with alkaline phosphatase-linked
antibody (1:10000; GE Healthcare) and detection by ECF
substrate. NPY and tubulin expression levels were calculated by
densitometry analysis (Bio-Rad Fluor MaxS software).
Injection of AAV into the rat arcuate nucleus
Recombinant AAV particles were generated as described before
[86,87]. The AAV plasmids were packaged into an AAV-1/2
chimerical capsid using AAV-1 and AAV-2 packaging plasmids in
a 50:50 ratio. The ability of AAV to transduce NPY positive cells
was evaluated by co-localization of NPY immunostaining (anti-
NPY 1:500; Sigma) with EGFP expression in rat primary cortical
neurons [88] and visualization on a confocal microscope (Zeiss).
Eighteen male Wistar rats weighing 210–230 g were randomly
divided into three groups (n=6 rats per group). Rats were
anesthetized with an intraperitoneal injection of ketamine/
xylazine (100 mg/kg and 20 mg/kg, respectively) and placed on
a stereotaxic frame. Injection was performed bilaterally into the
ARC following the coordinates: 2.60 mm posterior to the bregma,
0.5 mm lateral to the middle line and 9.55 mm ventral to the
brain surface. The control and the NPY silencing groups received
15.0610
9 v.g./side of AAV-hSyn-EGFP-miR-ctr and AAV-hSyn-
EGFP-miR-NPY, respectively (v.g., viral genomes), in a final
volume of 2 ml/side. The NPY overexpression group received
9.0610
9 v.g./side of AAV-hSyn-NPY, in a final volume of 2.5 ml/
side. Injection was performed at a rate of 0.5 ml/min with a 10 ml-
Hamilton syringe attached to an automatic Pump Controller
(WPI). Needle was kept in place for 10 minutes after end of
infusion. Rats were allowed to recover for 6 days. The ARC was
defined using The Paxino’s Rat Brain Atlas and AAV infection
was anatomically localized by EGFP-expressing neurons in the
ARC.
Food intake and body weight gain analysis
Rats were individually housed and monitored for eight-weeks
after AAV injection. Body weight was measured twice a week and
food intake once a week; during the food intake studies rats were
housed in hanging wire mesh cages. The testes to evaluate the
feeding response to food deprivation (FD) were carried as
described: basal food intake was measured on the 24-hours before
FD and then rats were food deprived for 36-hours. Next, rats were
re-fed with standard chow and food intake was measured on the
following 12-hours. Re-feeding was performed on different periods
of the day, precisely in the beginning of light period or dark
period, in the fourth and fifth week, respectively. Rats were
allowed to recover for six days with ad libitum access to food before
the next test. Activity was assessed on an activity box and number
of crossings was recorded, on basal condition and after 24-hours
on food deprivation, in the fifth week. Rats were always kept with
ad libitum access to water.
Collection of blood and tissues
Non-fasted rats were sacrificed 56 days after AAV injection by
lethaldoseofSodiumThiopental(Braun)andintracardiallyperfused
with 4% paraformaldehyde (PFA). Brains were removed and
epididymal fat was isolated and weighted. Samples from epididymal
adipose tissue were collected and immediately frozen in liquid
nitrogen or fixed in PFA. Prior to perfusion, blood was collected and
serum was separated by centrifugation (2 000 g, 15 minutes).
Serum analysis
Glycemia was measured using Accu-Check Blood Glucose
Sensor (Roche). ELISA kits were used to measure serum levels of
leptin and insulin (both from Millipore) and NPY peptide
(Phonenix Pharmaceuticals) following the manufacturer’s instruc-
tions. Other serum parameters were measured on an automated
Synchron Clinical System (Beckman Coulter).
Adipose tissue analysis
Fixed epididymal adipose tissue samples were sectioned to
twenty micrometers on a cryostat. Adipocytes auto-fluorescence
NPY in ARC and Energy Balance Alterations
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determined on a 0.75 mm
2 area, using the AxioVision software.
The obtained diameter values were grouped by size range and
adipocytes size distribution was determined as percentage of total
number of adipocytes evaluated. Protein extracts were obtained
from epididymal adipose tissue samples by homogenization of
tissue samples in RIPA lyses buffer, followed by sonication.
Afterwards, the homogenates were centrifuged and separated from
the fat layer with 23G needle. Fifteen micrograms of protein were
used for 12% polyacrylamide gel Glycine-SDS electrophoresis.
After blotting, the membrane was incubated with rabbit anti-
PPAR-gamma antibody (1:500; Santa Cruz) and mouse anti-actin
(1:5000, Sigma) following the protocol described above. Protein
expression levels were calculated by densitometry analysis (Bio-
Rad Fluor MaxS software).
Immunohistochemistry of brain slices
Immunohistochemistry was performed on brain sections using
the following primary antibodies: rabbit anti-NPY (1:6000,
Sigma), rabbit anti-AGRP (1:500, Phoenix Pharmaceuticals),
rabbit anti-POMC (1:500, Phoenix Pharmaceuticals) and rabbit
anti-CART (1:4000, Phoenix Pharmaceuticals). Briefly, thirty
micrometers brain coronal sections were blocked in PBS con-
taining 10% newborn goat serum (NGS; Gibco) and 0.3% Triton
X-100 (Sigma) and incubated in primary antibody overnight at
4uC. Sections were then incubated with goat anti-rabbit Alexa-
Flour 594 (1:200, Invitrogen) for one hour at room temperature.
Brain sections were observed on a Zeiss Axiovert microscope.
Determination of hypothalamic neuropeptides
immunoreactivity
Peptides immunoreactivity was determined on photographs of
immunohistochemical sections as described above. The ARC was
defined using The Paxino’s Rat Brain Atlas. Sections of
approximately equal spacing were sampled between Bregma
22.00 to 23.50 for NPY and AGRP immunoreactivity determi-
nation and Bregma 22.30 to 23.30 for POMC and CART
immunoreactivity determination. Multiple including was avoided
by analyzing non adjacent sections. For each peptide evaluated all
sections were simultaneously subjected to immunohistochemistry
procedure and to photographs acquisition. Images were taken on a
Zeiss Axiovert microscope with automated stage. An area that
includes the ARC or the nuclei DMH and VMH was encircled
and the mean grey value was measured for both hemispheres
separately using the ImageJ software. For each rat evaluated,
mean grey values from a total of 6 hemispheres for NPY and
AGRP and 4 hemispheres for POMC and CART were obtained.
Immunoreactivity was calculated by dividing the mean grey value
(arbitrary units) by the exposure time. Due to NPY expression
modulation, two different exposure times had to be used when
acquiring NPY immunostaining photographs. For the other
peptides, photographs were taken with the same exposure time.
Statistical methods
Results are expressed as mean and SEM. Neuropeptides
immunoreactivity, western-blot densitometry, epididymal fat pad
weight and serum parameters were analyzed by one-way ANOVA
followed by post hoc Bonferroni test. Cumulative body weight
gain, food intake and adipocytes size distribution were analyzed by
two-way ANOVA. Food intake and locomotor activity under
fasting conditions were analyzed by paired T-test.
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